Equity Investments	6 Months Ended
Jun. 30, 2026
Investments, Debt and Equity Securities [Abstract]
Equity Investments	Equity Investments (a) Nimbus The Company has no significant influence over Nimbus and accounts for its investment in Nimbus Therapeutics, LLC ("Nimbus") as a non-marketable security. As of both June 30, 2026 and December 31, 2025, the carrying value of the Nimbus investment was $2,436. The Company has no obligation to fund Nimbus' losses in excess of its initial investment. (b) Ajax In May 2021, the Company purchased 631,377 shares of Series B preferred stock of Ajax Therapeutics, Inc. ("Ajax"), a company co-founded by the Company, for $1,700 in cash. In April 2024, the Company purchased 1,416,450 shares of Series C preferred stock of Ajax for $3,000 in cash. In June 2026, in connection with the completion of Eli Lilly and Company’s acquisition of Ajax, the Company received a cash payment of approximately $57,180, comprised of $47,180 on account of the Company's equity stake in Ajax and $10,000 from a collaboration milestone payment. The Company is also eligible to receive additional cash payments upon the achievement by Ajax of specified clinical and regulatory milestones, as well as potential cash payments currently held in escrow related to the closing. During the three months ended June 30, 2026, the Company recognized a $42,144 gain from the change in fair value of its Ajax investment. Prior to the disposition of the Ajax investment, the Company valued its equity investment in Ajax as a non-marketable equity security as the Company did not exercise significant influence over Ajax. As of December 31, 2025, the carrying value of the Company’s investment in Ajax was $4,498. As of June 30, 2026, the Company no longer had an investment in Ajax. (c) Structure Therapeutics In July 2021, the Company purchased 494,035 shares of Series B preferred stock of Structure Therapeutics Inc. ("Structure Therapeutics") for $2,000 in cash. In April 2022, the Company purchased an additional 148,210 shares of Series B preferred stock for $600 in cash. On February 7, 2023, Structure Therapeutics completed its initial public offering ("IPO"). Immediately upon the closing of Structure Therapeutics' IPO, all of the outstanding Series B preferred stock automatically converted into ordinary shares on a one-for-one basis. The Company purchased 275,000 American Depository Shares ("ADSs") at $15.00 per ADS in the IPO. Each ADS represents three ordinary shares. The Company accounts for its investment in Structure Therapeutics at fair value based on the closing price of Structure Therapeutics' ADSs as of the reporting date. During the six months ended June 30, 2026, the Company sold a portion of its equity stake in Structure Therapeutics for net proceeds of $20,334. The Company recorded a mark-to-market gain of $1,050 on the portion of the investment sold during the six months ended June 30, 2026. During the three and six months ended June 30, 2026, the Company recorded a mark-to-market gain of $3,725 and a mark-to-market loss of $10,813, respectively, on the portion of the investment held at June 30, 2026. During the three and six months ended June 30, 2025, the Company reported a mark-to-market gain of $4,579 and a mark-to-market loss of $8,516, respectively, on the Structure Therapeutics investment. As of June 30, 2026 and December 31, 2025, the carrying value of the Company's investment in Structure Therapeutics was $36,544 and $66,641, respectively.

The Company has no significant influence over Nimbus and accounts for its investment in Nimbus Therapeutics, LLC ("Nimbus") as a non-marketable security. As of both June 30, 2026 and December 31, 2025, the carrying value of the Nimbus investment was $2,436. The Company has no obligation to fund Nimbus' losses in excess of its initial investment.

In May 2021, the Company purchased 631,377 shares of Series B preferred stock of Ajax Therapeutics, Inc. ("Ajax"), a company co-founded by the Company, for $1,700 in cash. In April 2024, the Company purchased 1,416,450 shares of Series C preferred stock of Ajax for $3,000 in cash.

In June 2026, in connection with the completion of Eli Lilly and Company’s acquisition of Ajax, the Company received a cash payment of approximately $57,180, comprised of $47,180 on account of the Company's equity stake in Ajax and $10,000 from a collaboration milestone payment. The Company is also eligible to receive additional cash payments upon the achievement by Ajax of specified clinical and regulatory milestones, as well as potential cash payments currently held in escrow related to the closing. During the three months ended June 30, 2026, the Company recognized a $42,144 gain from the change in fair value of its Ajax investment.

Prior to the disposition of the Ajax investment, the Company valued its equity investment in Ajax as a non-marketable equity security as the Company did not exercise significant influence over Ajax. As of December 31, 2025, the carrying value of the Company’s investment in Ajax was $4,498. As of June 30, 2026, the Company no longer had an investment in Ajax.

In July 2021, the Company purchased 494,035 shares of Series B preferred stock of Structure Therapeutics Inc. ("Structure Therapeutics") for $2,000 in cash. In April 2022, the Company purchased an additional 148,210 shares of Series B preferred stock for $600 in cash. On February 7, 2023, Structure Therapeutics completed its initial public offering ("IPO"). Immediately upon the closing of Structure Therapeutics' IPO, all of the outstanding Series B preferred stock automatically converted into ordinary shares on a one-for-one basis. The Company purchased 275,000 American Depository Shares ("ADSs") at $15.00 per ADS in the IPO. Each ADS represents three ordinary shares. The Company accounts for its investment in Structure Therapeutics at fair value based on the closing price of Structure Therapeutics' ADSs as of the reporting date.

During the six months ended June 30, 2026, the Company sold a portion of its equity stake in Structure Therapeutics for net proceeds of $20,334. The Company recorded a mark-to-market gain of $1,050 on the portion of the investment sold during the six months ended June 30, 2026. During the three and six months ended June 30, 2026, the Company recorded a mark-to-market gain of $3,725 and a mark-to-market loss of $10,813, respectively, on the portion of the investment held at June 30, 2026. During the three and six months ended June 30, 2025, the Company reported a mark-to-market gain of $4,579 and a mark-to-market loss of $8,516, respectively, on the Structure Therapeutics investment.